{"id":129,"date":"2015-01-15T08:56:22","date_gmt":"2015-01-15T13:56:22","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=129"},"modified":"2015-01-15T09:01:43","modified_gmt":"2015-01-15T14:01:43","slug":"ipoboutique-brief-january-15-2015-tbt-dicerna-ultragenyx","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/ipoboutique-brief-january-15-2015-tbt-dicerna-ultragenyx\/","title":{"rendered":"IPOBoutique Brief \u2013 January 15, 2015 \u2013 #TBT: Dicerna &#038; Ultragenyx"},"content":{"rendered":"<p>It\u2019s Thursday, so why not indulge the \u2018throw-back\u2019 nature of the day and look at a pair of biotechs from January 2014 that started the Healthcare crazy in the IPO market: <strong><a href=\"https:\/\/www.ipoboutique.com\/cgi\/info\/DicernaPharmaceuticalsInc-DRNA\" target=\"_blank\">Dicerna Pharmaceuticals (Nasdaq: DRNA)<\/a><\/strong> and <strong><a href=\"https:\/\/www.ipoboutique.com\/cgi\/info\/UltragenyxPharmaceutical-RARE\" target=\"_blank\">Ultragenyx Pharmaceuticals (Nasdaq: RARE)<\/a><\/strong>. These were two of 102 biotech deals that came to market in 2014 but the significance of the two is that they indicated a strong appetite for healthcare companies.<\/p>\n<p><!--more--><\/p>\n<p><strong>Dicerna Pharmaceuticals<\/strong> came to market on January 30, 2014 and opened with a 100% premium above the offering price. The gains were just getting started on day one as \u2018DRNA\u2019 traded as high as 207% above the offering price. That $46.00 first day high turned out to be the high for the year. A freefall from March 20 \u2013 to April 17 sent the stock from $41.00 to around $16.00\u2014a hair cut of around 61%. The biotech fell to a 52-week low of $8.00 in early November which was $7.00 below the offering price. What a roller coaster! Dicerna is now back above the offering price and closed for trading on Tuesday at $20.15.<\/p>\n<p><strong>Ultragenyx Pharmaceuticals<\/strong> came to market one day after Dicerna\u2014January 31. \u2018RARE\u2019 represented back-to-back major gains in biotech IPOs as the deal priced at $21.00 and opened at $45.80\u2014a 118% gainer at first trade. Within two months, Ultragenyx traded as high at $66.50 and held its gains in relative respect to \u2018DRNA\u2019. \u2018RARE\u2019 closed the day for trading on Tuesday at $53.99.<\/p>\n<p>IPO Boutique senior managing partner Scott Sweet rated both of these IPOs a \u20184\u2019 and the first-day gains proved to be strong. These two IPOs paved the way for strong biotechs later in the year such as <strong><a href=\"https:\/\/www.ipoboutique.com\/cgi\/info\/VersartisInc-VSAR\" target=\"_blank\">Versartis (Nasdaq: VSAR)<\/a><\/strong>, <a href=\"https:\/\/www.ipoboutique.com\/cgi\/info\/KitePharmaInc-KITE\" target=\"_blank\"><strong>Kite Pharma (Nasdaq: KITE)<\/strong><\/a>, <a href=\"https:\/\/www.ipoboutique.com\/cgi\/info\/AvalancheBiotechnologiesInc-AAVL\" target=\"_blank\"><strong>Avalanche Biotechnologies (Nasdaq: AAVL)<\/strong><\/a> and<a href=\"https:\/\/www.ipoboutique.com\/cgi\/info\/JunoTherapeutics-JUNO\" target=\"_blank\"><strong> Juno Pharmaceuticals (Nasdaq: JUNO)<\/strong><\/a>.<\/p>\n<p><strong>IPO scheduled for January 28<\/strong><\/p>\n<p><a href=\"https:\/\/www.ipoboutique.com\/cgi\/info\/PresbiaPLC-LENS-info.php\" target=\"_blank\"><strong>Presbia plc (Nasdaq: LENS)<\/strong><\/a> updated terms for its IPO on Thursday morning. They are an ophthalmic device company that has developed and is currently marketing a proprietary optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. They plan to offer 4.2 million shares at a $11-$13 range.<\/p>\n<p><strong>First Postponement of 2015<\/strong><\/p>\n<p>The first postponement of 2015 goes to <a href=\"https:\/\/www.ipoboutique.com\/cgi\/info\/SutherlandAssetManagement-SLD-info.php\" target=\"_blank\"><strong>Sutherland Asset Management (NYSE:SLD)<\/strong><\/a>. The real estate finance company acquires, originates, manages, services and finances primarily small-balance commercial loans, or SBC loans. J.P. Morgan, Morgan Stanley &amp; FBR were the lead underwriters on the deal.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>It\u2019s Thursday, so why not indulge the \u2018throw-back\u2019 nature of the day and look at a pair of biotechs from January 2014 that started the Healthcare crazy in the IPO market: Dicerna Pharmaceuticals (Nasdaq: DRNA) and Ultragenyx Pharmaceuticals (Nasdaq: RARE). These were two of 102 biotech deals that came to market in 2014 but the[&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[1],"tags":[18,14,19,17,20,15,4,16],"class_list":["post-129","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-aavl","tag-drna","tag-juno","tag-kite","tag-lens","tag-rare","tag-sld","tag-vsar"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/129","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=129"}],"version-history":[{"count":2,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/129\/revisions"}],"predecessor-version":[{"id":131,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/129\/revisions\/131"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=129"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=129"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}